Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3339-3346

  Santin, Alessandro D ^a   Bellone, Stefania ^a   Siegel, Eric R ^a   McKenney, Jesse K ^a   Thomas, Maria ^a   Roman, Juan J ^a   Burnett, Alexander ^a   Tognon, Germana ^b   Bandiera, Elisabetta ^b   Pecorelli, Sergio ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; CLAUDIN 3; CLAUDIN 3 RECEPTOR; CLAUDIN 4; CLAUDIN 4 RECEPTOR; FORMALDEHYDE; MEMBRANE RECEPTOR; PARAFFIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR NECROSIS; UTERUS CARCINOMA; XENOGRAFT;

AGED; AGED, 80 AND OVER; ANIMALS; CARCINOSARCOMA; CLOSTRIDIUM PERFRINGENS; ENTEROTOXINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; UTERINE NEOPLASMS;

EID: 34250618299     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-3037     Document Type: Article

References (13)

1. Arrastia CD, Fruchter RG, Clark M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 1997;65:158-63.
2. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-96.
3. Santin AD, Cane S, Bellone S, et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 2005;65:4334-42.
4. Santin AD, Zhan F, Cané S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novelmolecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005;92:1561-73.
5. Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 1977;136:1239-47.
6. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. JBiol Chem 1997;272:26652-8.
7. McClane BA. An overview of Clostridium perfringens enterotoxin. Toxicon 1996;34:1335-43.
8. Kokai-Kun JF, McClane BA. Evidence that a region(s) of the Clostridium perfringens enterotoxin molecule remains exposed on the external surface of the mammalian plasma membrane when the toxin is sequestered in small or large complexes. Infect Immun 1996;64:1020-5.
9. Kokai-Kun JF, McClane BA. Determination of functional regions of Clostridium perfringens enterotoxin through deletion analysis. Clin Infect Dis 1977;25 Suppl 2:S165-7.
10. Kokai-Kun JF, McClane BA. Deletion analysis of the Clostridium perfringens enterotoxin. Infect Immun 1997;65:1014-22.
11. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90.
12. Agarwal R, D'Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005;65:7378-85.
13. Michl P, Bu chholz M, Rolke M, et al. Clau din-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001;121:678-84.